Pharmaxis All Financial Data in US $ (mln)Show in reporting currency
Worldwide  
  Overview  


EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile
Profile Pharmaxis, an Australian pharmaceutical company focused on development of therapeutic products for the treatment of chronic respiratory and autoimmune diseases.
Listed or Private Company Listed
Company Classification Biotechnology
Company Website Website

Full Company Profile Information

EventAnalyzer - Last Key Event
Closing Price DateClosing Price Date EventAnalyzer Note Market Cap (US $m) Change (%) Change (+$m)
12/2/2009 1 Dec: Company announces headline results for its phase III trial of Bronchitol in patients with cystic fibrosis, in which the drug shows a significant improvement in lung function. 521 10.8% 51
Top 3 Products (Worldwide Sales 2007/08)
Annual Sales WW - Sales Growth per Year (%)
Rank1 Product Generic Name Therapeutic Subcategory 2007 2008 2008
1 Aridol mannitol Other respiratory agents 02 03 -6%
Note: Shaded Cells4
Therapy Area Focus in 2008
Pharmaxis
2008
 WW Rx & OTC Sales By Therapy Area
  Main Categories
     Respiratory 0
     Other Rx & OTC Pharma 0
EvaluatePharma® Coverage of Marketed and Pipeline Products
Product Count
Pharmaxis 5 12

Register to access more FREE content:

  • 2009 Product Sales analysis
  • 2009 Pharmaceutical Sales
  • 2009 Market Share & Global Ranking
  • Download to Excel
  • Search 2 yrs of company press releases